Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI +14.58% Days Sales Outstanding is 0.00 as of Jun. 2026. The stock has 1 warning sign investors should review. Among 947 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 105596.52% on this metric.
The historical rank and industry rank for Petros Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
During the past 7 years, Petros Pharmaceuticals's highest Days Sales Outstanding was 177.76. The lowest was 61.04. And the median was 139.04.
PTPI's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 71.98 * Ranked among companies with meaningful Days Sales Outstanding only.
Petros Pharmaceuticals's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Petros Pharmaceuticals (OTCPK:PTPI) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Petros Pharmaceuticals Days Sales Outstanding Related Terms
Petros Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals Days Sales Outstanding Chart
PTPI vs GRPS, KOAN, OWPC: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Days Sales Outstanding falls into.
Petros Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Petros Pharmaceuticals and its competitors. Over the past decade, Petros Pharmaceuticals' Days Sales Outstanding has ranged from 61.04 to 177.76. According to the industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 947 companies in the Drug Manufacturers industry.
Is Petros Pharmaceuticals' Days Sales Outstanding too high?
Petros Pharmaceuticals' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 61.04 to a high of 177.76. Based on the distribution chart, Petros Pharmaceuticals ranks #999999 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Petros Pharmaceuticals' Days Sales Outstanding compare to GRPS and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 947 companies for Days Sales Outstanding. This places Petros Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Historically, Petros Pharmaceuticals' own Days Sales Outstanding has ranged from 61.04 to 177.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
